Array BioPharma (ARRY)
Array BioPharma Revenues: 19.11M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ARRY Revenues Rankings
| Overall | 21st percentile | 3485 of 4425 |
| Sector | 44th percentile | 263 of 470 in Healthcare |
| Industry | 62nd percentile | 49 of 132 in Biotechnology |
ARRY Revenues Range, Past 5 Years
| Minimum | 5.507M | Jun 2009 |
| Maximum | 23.23M | Dec 2011 |
| Average | 12.60M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these ARRY related companies
ARRY News
$AMRN Marine 889 patent prosecution update http://stks.co/3tFJ $ARRY $GALE $VTUS $PFE $KERX
about 9 days ago by imhobutdydd
about 9 days ago by imhobutdydd
$FFN http://stks.co/3sxu $FFN $GALE $PSOF $ARRY Full blog post and video here http://stks.co/3sxv
about 10 days ago by LincolnList
about 10 days ago by LincolnList
$AMRN Marine 889 patent prosecution update http://stks.co/3soe $ARRY $GALE $VTUS $PFE $KERX
about 10 days ago by imhobutdydd
about 10 days ago by imhobutdydd
Movers: $FFN #FriendFinder1.52+37 $KONG KongZhong6.56+64 $ARRY ArrayBioPh3.74+09YH $ZNGA #Zynga8.21 $MEG MediaGen4.16+1 http://stks.co/3siH
about 10 days ago by InvestorsGuru
about 10 days ago by InvestorsGuru
Notable 52-Week Highs and Lows of the Day 05/17: (ARRY) (NTES) (PCYC) High; (WFR) (VALE) (CLWR) Low
May 17, 3:42PM Street Insider
May 17, 3:42PM Street Insider
Array BioPharma, RCM Technologies, Other Stocks Hit 52-Week Highs Thursday
May 17, 12:31PM Fox Business
May 17, 12:31PM Fox Business
$ARRY Mentioned more than normal on StockTwits - Currently at 8 x average daily social activity
about 10 days ago by TradeIdeasQuant
about 10 days ago by TradeIdeasQuant
$ARRY is -5.5% down since open on unusual high volume but still 2.7% up since close.
about 10 days ago by TradeBot
about 10 days ago by TradeBot
RT @justfurkids ASCO12 "Most significant cancer drug data came from $AVEO $EXEL & phase II studies by $ARRY " http://stks.co/3rgp
about 11 days ago by russe9
about 11 days ago by russe9
ASCO12 "Most significant cancer drug data came from phase III studies by $AVEO $EXEL & phase II studies by $ARRY " http://stks.co/3rgj
about 11 days ago by justfurkids
about 11 days ago by justfurkids
Array BioPharma Announces Clinical Data Presentations at the 2012 ASCO Annual Meeting
May 16, 4:00PM Business Wire
May 16, 4:00PM Business Wire
RT @adamfeuerstein Orbimed Advisors top 5 new buys in Q1: $ONXX $CCXI $IMGN $NBIX $ARRY, per 13F #biotech
about 11 days ago by WolfsBiotechs
about 11 days ago by WolfsBiotechs
Array BioPharma and Genentech's Strategic Alliance Voted Breakthrough Alliance of 2012
May 14, 6:30PM Business Wire
May 14, 6:30PM Business Wire
Listen to $ARRY Q3 2012 earnings call - live at 09:00 AM, ondemand after - http://stks.co/3bA4
about 26 days ago by earningscast
about 26 days ago by earningscast
Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2012
Apr 30, 4:00PM Business Wire
Apr 30, 4:00PM Business Wire
http://stks.co/3aI7 Earnings after hours: $ADVS $ARRY $APC $FST, $JEC, $KAMN, $VECO, $SFLY
about 27 days ago by freefdawatchlistcom
about 27 days ago by freefdawatchlistcom
Array BioPharma Names Liam Ratcliffe, M.D., Ph.D., to Board of Directors
Apr 30, 8:00AM Business Wire
Apr 30, 8:00AM Business Wire
Array BioPharma to Report Financial Results for the Third Quarter of Fiscal 2012 on April 30, 2012
Apr 23, 4:01PM Business Wire
Apr 23, 4:01PM Business Wire
Array BioPharma Names Howard Holden, Ph.D., Vice President of Regulatory Affairs and Quality Assurance
Apr 16, 8:30AM Business Wire
Apr 16, 8:30AM Business Wire
Encouraging Selumetinib Results Announced for Phase 2 Trial in Ovarian Cancer
Apr 04, 9:29AM Business Wire
Apr 04, 9:29AM Business Wire
Array BioPharma to Present at the Cowen and Company 32nd Annual Health Care Conference
Feb 27, 1:00PM Business Wire
Feb 27, 1:00PM Business Wire
Piper Jaffray Maintains Array Biopharma at Neutral, Lowers PT from $4 to $3.5
Feb 15, 9:02AM Benzinga
Feb 15, 9:02AM Benzinga
Array BioPharma Announces Closing of Public Offering of Common Stock and Exercise of Overallotment Option
Feb 14, 9:57AM Business Wire
Feb 14, 9:57AM Business Wire
Array BioPharma to Present at the Leerink Swann Global Healthcare Conference
Feb 09, 5:30PM Business Wire
Feb 09, 5:30PM Business Wire
Array BioPharma (ARRY) Prices 20 Milllion Share Offering at $2.60/Share
Feb 09, 9:04AM Street Insider
Feb 09, 9:04AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ARRY | 3.46 | -0.19 | -5.21% | 282.16M |
| ARRS | 12.32 | -0.01 | -0.08% | 1.418B |
| ARR | 6.95 | +0.05 | +0.72% | 984.88M |
| ARQL | 5.87 | +0.05 | +0.86% | 316.69M |
| AROW | 23.85 | -0.05 | -0.21% | 283.82M |
| ARO | 19.19 | +0.17 | +0.89% | 1.554B |
| ARNA | 6.00 | -0.04 | -0.66% | 1.083B |
| ARMH | 23.23 | +0.13 | +0.56% | 10.46B |
| ARLP | 58.99 | +0.17 | +0.29% | 2.176B |
| ARL | 2.69 | +0.00 | +0.00% | 30.99M |
